BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 27025939)

  • 1. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
    De Bus L; Denys W; Catteeuw J; Gadeyne B; Vermeulen K; Boelens J; Claeys G; De Waele JJ; Decruyenaere J; Depuydt PO
    Intensive Care Med; 2016 Jun; 42(6):1029-39. PubMed ID: 27025939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program.
    Liu P; Ohl C; Johnson J; Williamson J; Beardsley J; Luther V
    BMC Infect Dis; 2016 Dec; 16(1):751. PubMed ID: 27955625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
    Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
    Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
    Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.
    Mokart D; Slehofer G; Lambert J; Sannini A; Chow-Chine L; Brun JP; Berger P; Duran S; Faucher M; Blache JL; Saillard C; Vey N; Leone M
    Intensive Care Med; 2014 Jan; 40(1):41-9. PubMed ID: 24231857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
    Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
    Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.
    Leone M; Bechis C; Baumstarck K; Lefrant JY; Albanèse J; Jaber S; Lepape A; Constantin JM; Papazian L; Bruder N; Allaouchiche B; Bézulier K; Antonini F; Textoris J; Martin C;
    Intensive Care Med; 2014 Oct; 40(10):1399-408. PubMed ID: 25091790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of broad-spectrum beta-lactam prescriptions (except carbapenems) in a French teaching hospital.
    Nguyen S; Lefébure A; Lescure FX; Arnaud P; Rioux C
    Med Mal Infect; 2018 Dec; 48(8):509-515. PubMed ID: 29941336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.
    Carlier M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4689-94. PubMed ID: 26014946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infections.
    Montravers P; Augustin P; Grall N; Desmard M; Allou N; Marmuse JP; Guglielminotti J
    Crit Care; 2016 Apr; 20():83. PubMed ID: 27052675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.
    Janowski AB; Michaels MG; Martin JM; Green MD
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):342-5. PubMed ID: 26407269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study.
    Alvarez-Lerma F; Alvarez B; Luque P; Ruiz F; Dominguez-Roldan JM; Quintana E; Sanz-Rodriguez C;
    Crit Care; 2006; 10(3):R78. PubMed ID: 16704742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of antibiotic de-escalation in patients with ventilator-associated pneumonia in Malaysia.
    Khan RA; Aziz Z
    Int J Clin Pharm; 2017 Aug; 39(4):906-912. PubMed ID: 28643112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study.
    Trupka T; Fisher K; Micek ST; Juang P; Kollef MH
    Crit Care; 2017 Jul; 21(1):180. PubMed ID: 28709439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
    Trials; 2015 Jan; 16():24. PubMed ID: 25623485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.